XOMA’s (XOMA) Buy Rating Reiterated at HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $74.00 price target on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 188.61% from the company’s current price.

XOMA Price Performance

XOMA stock opened at $25.64 on Thursday. The firm has a market cap of $298.45 million, a price-to-earnings ratio of -6.35 and a beta of 0.58. The company has a quick ratio of 8.68, a current ratio of 8.68 and a debt-to-equity ratio of 1.34. XOMA has a 12-month low of $13.48 and a 12-month high of $27.00. The company’s fifty day simple moving average is $24.69 and its 200 day simple moving average is $20.30.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. On average, analysts expect that XOMA will post -1.73 earnings per share for the current year.

Hedge Funds Weigh In On XOMA

An institutional investor recently bought a new position in XOMA stock. Barclays PLC bought a new position in shares of XOMA Co. (NASDAQ:XOMA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,468 shares of the biotechnology company’s stock, valued at approximately $28,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.